| Literature DB >> 35686662 |
Nastaran Barati1,2, Seyedmousa Motavallihaghi3, Banafsheh Nikfar4, Shahla Chaichian4, Amir Abbas Momtazi-Borojeni5.
Abstract
COVID-19 is a critical pandemic that affected communities around the world, and there is currently no specific drug treatment for it. The virus enters the human cells via spikes and induces cytokine production and finally arrests the cell cycle. Ivermectin shows therapeutic potential for treating COVID-19 infection based on in vitro studies. Docking studies have shown a strong affinity between Ivermectin and some virulence factors of COVID-19. Notably, clinical evidence has demonstrated that Ivermectin with usual doses is effective by both the prophylactic and therapeutic approaches in all phases of the disease. Ivermectin inhibits both the adhesion and replication of the virus. Local therapy of the lung with Ivermectin or combination therapy may get better results and decrease the dose of the drug.Entities:
Keywords: COVID-19; Ivermectin; SARS-CoV-2; hypoxia-inducible factor-alpha; importin; inflammation; lung; pandemics
Mesh:
Substances:
Year: 2022 PMID: 35686662 PMCID: PMC9442455 DOI: 10.1177/15353702221099579
Source DB: PubMed Journal: Exp Biol Med (Maywood) ISSN: 1535-3699